Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

 

 Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately £12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

 

Open Orphan plc

Cathal Friel, Chief Executive Officer

 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPUNUARRRUAAUR
Date   Source Headline
12th Dec 20194:41 pmRNSForm 8.3 - Open Orphan PLC
11th Dec 20194:03 pmRNSForm 8.3 - Open Orphan
11th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 201911:13 amGNWForm 8.3 - Open Orphan
11th Dec 20197:00 amRNSForm 8 (OPD)
10th Dec 20194:43 pmRNSForm 8 (DD) Open Orphan plc
10th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
10th Dec 20199:59 amPRNForm 8.3 - Open Orphan
10th Dec 20197:00 amRNSRule 2.9 Announcement
9th Dec 20191:27 pmRNSTotal Voting Rights
9th Dec 201912:21 pmPRNForm 8.3 - Open Orphan Plc
9th Dec 20197:00 amRNSRecommended All-Equity Offer
25th Nov 20197:00 amRNSEarly adopters signed for Genomic Health DataBANK
18th Nov 20197:00 amRNSContract signed with Carna Bioscience
15th Nov 20197:00 amRNSJefferies 2019 London Healthcare Conference
11th Nov 20197:00 amRNSPreferred Partner Agreement
24th Oct 20197:00 amRNSValue the Markets Webinar
21st Oct 20197:00 amRNSInvestor Event Attendance and Presentation
15th Oct 20197:00 amRNSAgreement signed with Empiric Logic
8th Oct 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Oct 20193:58 pmRNSResult of AGM
1st Oct 201911:08 amRNSHolding(s) in Company
27th Sep 20198:00 amRNSEuronext Growth Dublin Notice
25th Sep 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
23rd Sep 20193:39 pmRNSExercise of Warrants and Issue of Shares
16th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
12th Sep 20197:00 amRNSNotice of AGM
10th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
9th Sep 20197:00 amRNSInvestor Event Attendance and Presentation
3rd Sep 20197:00 amRNSInvestor Event Attendance and Presentation
2nd Sep 20197:00 amRNSUpcoming Investor Events
1st Aug 20197:00 amRNSDirectorate Changes
30th Jul 20198:00 amRNSEuronext Growth Dublin Notice
25th Jul 20197:00 amRNSExercise of Warrants and Issue of Shares
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
12th Jul 20197:00 amRNSIntegumen Shares
9th Jul 20195:26 pmRNSHolding(s) in Company
28th Jun 20198:00 amRNSEuronext Growth Dublin Notice
28th Jun 20197:59 amRNSEuronext Growth Dublin Cancellation Notice
28th Jun 20197:00 amRNSFirst Day of Dealings and Re-admission
25th Jun 20191:24 pmRNSDirectorate Update
14th Jun 201912:13 pmRNSEuronext Growth - Schedule One
14th Jun 201911:00 amRNSSchedule One - Ven Life Sciences Holdings plc
11th Jun 20197:30 amRNSEuronext Growth Dublin Market Restoration Notice
11th Jun 20197:30 amRNSRestoration - Venn Life Sciences Holding Plc
11th Jun 20197:01 amRNSPlacing of Shares
11th Jun 20197:00 amRNSAudited Final Results
10th May 20197:30 amRNSEuronext Growth Dublin Suspension Notice
10th May 20197:30 amRNSSuspension - Venn Life Sciences Holdings Plc
10th May 20197:01 amRNSConditional Acquisition of Open Orphan DAC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.